This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Wed Jul 1, 9:42AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palisade Bio (PALI) and Sarepta Therapeutics (SRPT) with bullish sentiments.

End of Quarter Sale - 70% Off

Palisade Bio (PALI)

Maxim Group analyst Naz Rahman reiterated a Buy rating on Palisade Bio yesterday and set a price target of $8.00. The company’s shares closed last Tuesday at $2.16.

According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.0% and a 37.9% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Galmed Pharmaceuticals, Xtant Medical Holdings, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Palisade Bio is a Strong Buy with an average price target of $10.14, a 360.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

See today’s best-performing stocks on TipRanks >>

Sarepta Therapeutics (SRPT)

Wedbush analyst Yun Zhong maintained a Buy rating on Sarepta Therapeutics today and set a price target of $35.00. The company’s shares closed last Tuesday at $17.67.

According to TipRanks.com, Zhong is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.8% and a 41.3% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, CAMP4 Therapeutics Corporation, and MoonLake Immunotherapeutics. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $23.00 average price target.

Read More on PALI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).